Plasma prolidase levels are high in schizophrenia but not in first-episode psychosis
International Clinical Psychopharmacology, cilt.36, sa.1, ss.25-29, 2021 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 36 Sayı: 1
- Basım Tarihi: 2021
- Doi Numarası: 10.1097/yic.0000000000000329
- Dergi Adı: International Clinical Psychopharmacology
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, BIOSIS, EMBASE, MEDLINE, Psycinfo
- Sayfa Sayıları: ss.25-29
- Anahtar Kelimeler: drug naive, first-episode psychosis, prolidase, schizophrenia
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
An increasing number of studies have focussed on the neurobiology of schizophrenia (SCH), contributing to a better understanding of this disorder. Prolidase is a metalloprotease found in various tissues, which has been associated with the concentrations of proline, a neurotransmitter, in the brain. There is evidence to suggest that elevated proline levels play a role in SCH. The aim of the present study was to compare plasma proline levels in patients with drug-naive first-episode psychosis (FEP) and in those with SCH. Patients diagnosed with FEP (n = 26) and SCH (n = 26) were recruited for this study, in addition to healthy control volunteers (n = 26). Plasma prolidase levels were found to be elevated in the SCH group compared to drug-naive FEP and healthy control groups. This finding indicates that prolidase levels are higher in SCH patients, while levels in patients with drug-naive FEP are similar to those of healthy control. Follow-up studies are needed to provide a better understanding of prolidase in the etiopathogenesis of SCH.